B133
Late effects associated with treatments for breast, colorectal and prostate cancer - a matched cohort study using the General Practice Research Database and National Cancer Intelligence Network
Nada Khan, Peter Rose
University of Oxford, UK
Background
There is evidence that cancer treatment can lead to adverse health outcomes in cancer survivors. Because the population of cancer survivors is increasing, there is a greater need to understand these late effects and provide targeted care to this population who are usually cared for in primary care
Method
This study involves a matched cohort study extracted from the General Practice Research Database (GPRD), with longitudinal primary care data on long-term survivors of breast, colorectal and prostate cancer (n=29244) matched to 4 controls (n=116418) on age, gender and practice. We will compare the incidence of new diagnoses related to cancer treatment, including heart failure, erectile dysfunction, osteoporosis, bowel/bladder dysfunction and lymphoedema.
GPRD data will be linked with additional cancer registration and cancer treatment data from the National Cancer Intelligence Network (NCIN) in summer 2009.
Results
Our initial analyses suggest that long-term breast cancer survivors have an increased odds of developing heart failure compared with non-cancer matched controls (OR = 1.33, 95% CI 1.12-1.64). There is strong evidence for a positive association between a diagnosis of osteoporosis in breast (OR = 1.08, 1.01-1.16)
and prostate cancer survivors (OR = 1.51, 95% CI 1.28-1.77) compared with controls. Cancer treatment data is not well recorded in primary care, therefore we intend to complete and refine the analyses using NCIN treatment data. We will present outcome data by treatment modality for each cancer site.
Conclusion
There is evidence for an increased risk of late effects in survivors of breast and prostate cancer based on initial analyses. The key element of looking at late effects of treatment is good quality data on individual level cancer treatment. We intend to link with NCIN treatment data in summer 2009, which will allow us to present the final analyses on late effects of treatment for breast, colorectal and prostate cancer.
